Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
8
NMRA Quote, Financials, Valuation and Earnings
Last price:
$0.63
Seasonality move
:
-29.59%
Day range:
$0.63 - $0.69
52-week range:
$0.62 - $17.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.36x
Volume:
1M
Avg. volume:
1.2M
1-year change:
-94.25%
Market cap:
$102M
Revenue:
--
EPS (TTM):
-$1.53
Analysts' Opinion
-
Consensus RatingNeumora Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.29, Neumora Therapeutics has an estimated upside of 898.41% from its current price of $0.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.63.
Fair Value
-
According to the consensus of 6 analysts, Neumora Therapeutics has 898.41% upside to fair value with a price target of $6.29 per share.
NMRA vs. S&P 500
-
Over the past 5 trading days, Neumora Therapeutics has underperformed the S&P 500 by -15.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Neumora Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neumora Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Neumora Therapeutics reported revenues of --.
Earnings Growth
-
Neumora Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Neumora Therapeutics reported earnings per share of -$0.37.
Enterprise value:
-205.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$135.9M | -$252.1M | -$263.5M | -$114M | -$62.9M | |
| EBITDA | -$135.3M | -$251.4M | -$262.8M | -$113.8M | -$62.8M | |
| Diluted EPS | -$0.86 | -$2.31 | -$1.53 | -$0.68 | -$0.37 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $193.8M | $415.6M | $388M | $478.3M | $314.1M | |
| Total Assets | $197.9M | $429.3M | $426.2M | $496.2M | $317M | |
| Current Liabilities | $9.4M | $23.3M | $23.7M | $25.1M | $29.9M | |
| Total Liabilities | $292.3M | $754.5M | $873.1M | $27.1M | $29.9M | |
| Total Equity | -$94.4M | -$325.2M | -$446.9M | $469.1M | $287.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$114.9M | -$163.3M | -$182.9M | -$51.4M | -$50.3M | |
| Cash From Investing | -$168M | $64.4M | -$70.6M | $13.7M | -$98.8M | |
| Cash From Financing | $115.7M | $231.9M | $21.6M | -$481K | $15.6M | |
| Free Cash Flow | -$115.4M | -$163.4M | -$182.9M | -$51.5M | -$50.3M | |
NMRA
Sector
Market Cap
$102M
$35M
Price % of 52-Week High
3.67%
41.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-94.25%
-43.29%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.70
200-day SMA
Sell
Level
$8.17
Bollinger Bands (100)
Sell
Level
0.08 - 8.1
Chaikin Money Flow
Sell
Level
-41M
20-day SMA
Sell
Level
$0.89
Relative Strength Index (RSI14)
Sell
Level
20.43
ADX Line
Sell
Level
60.83
Williams %R
Buy
Level
-98.2338
50-day SMA
Sell
Level
$1.31
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-20.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Stock Forecast FAQ
In the current month, NMRA has received 1 Buy ratings 5 Hold ratings, and 0 Sell ratings. The NMRA average analyst price target in the past 3 months is $6.29.
-
Where Will Neumora Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neumora Therapeutics share price will rise to $6.29 per share over the next 12 months.
-
What Do Analysts Say About Neumora Therapeutics?
Analysts are divided on their view about Neumora Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neumora Therapeutics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Neumora Therapeutics's Price Target?
The price target for Neumora Therapeutics over the next 1-year time period is forecast to be $6.29 according to 6 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is NMRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neumora Therapeutics is a Hold. 5 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NMRA?
You can purchase shares of Neumora Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neumora Therapeutics shares.
-
What Is The Neumora Therapeutics Share Price Today?
Neumora Therapeutics was last trading at $0.63 per share. This represents the most recent stock quote for Neumora Therapeutics. Yesterday, Neumora Therapeutics closed at $0.63 per share.
-
How To Buy Neumora Therapeutics Stock Online?
In order to purchase Neumora Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 10.95% over the past day.
Sell
50
IBKR alert for Apr 17
Interactive Brokers Group [IBKR] is down 8.97% over the past day.
Sell
39
FNGA alert for Apr 17
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 9.37% over the past day.
